Effort to find opioid alternatives could make cannabis biotechs an M&A target

Following Trump’s recent announcement to reduce opioid addiction, it’s logical to wonder when Big Pharma may commit to developing cannabis-based pain alternatives. If they do, will they develop their own R&D, or buy their way into the market?

Given the risks and costs involved with starting up in the cannabis industry, M&A may be the favored route. Activity has been strong, with M&A transactions hitting $59.3 billion in 2015. Some of the companies involved include CannaRoyalty (OTC: CNNRF), Aphria (OTC: APHQF), Maricann Group (CSE: MARI) and Aurora Cannabis (OTC: ACBFF).

In August, Aphria announced an $11.5 million investment in Scientus Pharma, a biopharma firm researching cannabinoids. In the same month, Maricann purchased NanoLeaf Technologies, known for a standardized dose soft gel capsule for CBD-based pharmaceutical Vesisob, co-developed with Vesifact. In September, Aurora Cannabis bought Hempco.

One company that appears to look for a suitor is Vancouver-based cannabis biopharmaceutical InMed Pharmaceuticals Inc (CSE: IN) (OTC: IMLFF).

InMed has a proprietary cannabinoid biosynthesis process. Biosynthesis mimics a plant’s cannabinoid-creation process to create pure cannabinoids free of the impurities often found in extraction. With the value of the CBD market in the U.S expected to hit $2.1 billion by 2020, InMed feels its biosynthesis intellectual property value could be substantial.

The firm is a pre-clinical stage company developing novel therapies through R&D into the pharmacology of cannabinoids.

InMed stock traded up 12% today to $0.45. It’s market cap $57.37million.

Source InMed

Effort to find opioid alternatives could make cannabis biotechs an M&A target

About Cannin: Your Cannabis Stocks Resource

Cannin is your #1 trusted resource for cannabis stocks. Our global team of experts evaluates all emerging cannabis stock investing opportunities. We aggregate hundreds of hours of financial research and provide tips on the best cannabis stocks for 2020.

Use Cannin as your resource for:

Market analysts expect the marijuana and hemp industry will have an annual value exceeding $75 Billion in the next decade. Is it too late to invest in marijuana stocks? No! This is the perfect time to invest.

Are you looking to buy stock in hemp companies or marijuana companies for 2020? Interested in new penny hemp stock companies? Looking for the best Canadian cannabis stocks to invest in? Looking to leverage the power of algorithmic stock trading to beat the cannabis market? We can help.

Are you interested in cannabis stocks like Curaleaf, Trulieve, Aurora Cannabis, Charlotte’s Web, Canopy Growth, or Hemp Inc.?

Predict price movements of cannabis stocks several hours in advance with our proprietary algorithmic stock trading software.

+25% Gains in 2020
+49.8% Gains in 2019
Backtested since 2012

We’re so confident you’ll love our algotrading cannabis stock signals, we’re willing to give you a one-month risk-free trial to see it for yourself.

Profit from the best cannabis stocks – we’ll show you how at cannin.com.

Marijuana Stocks, Pot Stocks, Algorithmic Stock Trading, Investing in Hemp Stocks

Effort to find opioid alternatives could make cannabis biotechs an M&A target